Trial Profile
A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 23 May 2017 Results published in the Clinical Infectious Diseases
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.